Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Announces Earnings Results

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued its quarterly earnings results on Wednesday. The company reported $0.18 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.18, reports. Bayer Aktiengesellschaft had a positive return on equity of 15.35% and a negative net margin of 8.51%.The company had revenue of $13.24 billion for the quarter, compared to the consensus estimate of $13.08 billion. Bayer Aktiengesellschaft updated its FY 2026 guidance to 1.251-1.400 EPS.

Bayer Aktiengesellschaft Trading Down 0.9%

Shares of Bayer Aktiengesellschaft stock opened at $10.91 on Friday. The company’s fifty day moving average price is $12.43 and its two-hundred day moving average price is $9.88. The firm has a market capitalization of $42.88 billion, a PE ratio of -9.83, a price-to-earnings-growth ratio of 4.36 and a beta of 0.69. Bayer Aktiengesellschaft has a 52-week low of $5.30 and a 52-week high of $14.85. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71.

Analyst Upgrades and Downgrades

BAYRY has been the topic of a number of research analyst reports. DZ Bank lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a report on Wednesday, February 18th. JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Zacks Research lowered shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 23rd. Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Finally, Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Bayer Aktiengesellschaft presently has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.